Haleon

Q3 miss; guidance downgraded; recovery delayed

29/10/26 -"Haleon’s Q3 sales missed expectations. While Oral Health was again the main driver of Q3 results, full-year topline guidance was lowered due to weakness in some other key businesses. We are likely to ..."

PDF page sample
Pages
60
Language
English
Published on
29/10/26
Download
You may also be interested by these reports :
29/10/26
Unilever delivered another solid quarter, with volumes more resilient than expected despite accelerating pricing. Emerging markets and HPC remain the ...
29/10/26
Haleon’s Q3 sales missed expectations. While Oral Health was again the main driver of Q3 results, full-year topline guidance was lowered due to ...
29/10/26
Henkel reported a positive set of preliminary Q3 2026 sales numbers. The strong organic growth was primarily supported by pricing with a modest ...
29/10/26
BIC’s Q3 FY26 organic sales fell 0.6% yoy, in line with expectations, as growth in Blade Excellence partly offset weakness in Stationery and ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO